German science and technology group Merck is open to more acquisitions for its Life Science business after announcing in May ...

DSNKY), and Merck (MRK), respectively. Meanwhile, Moderna (MRNA) climbed 15 places to fifth in the Invention Index. The ...

Merck & Co. has picked up options on two Evaxion Biotech vaccine candidates, paying $3.2 million and dangling more than $1 billion in milestones for the chance to pick up preclinical prospects ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

Moderna and Merck also are jointly developing a cancer ... which is based in Cambridge, Massachusetts. The randomized study evaluated the safety, reactions and immune response in people who ...

A privately held clinical-stage biotechnology company headquartered in Cambridge, Massachusetts ... In collaboration with Merck, Moderna is also conducting a phase 1 study of MRK-1777, an mRNA ...

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively. ALAMEDA ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, will hold its third-quarter 2024 sales and earnings conference call with institutional ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive top-line results from its pivotal Phase 3 trial (V503-064 ...

Bristol Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) and Merck's (NYSE:MRK) Keytruda (pembrolizumab), two highly popular checkpoint inhibitors used in the treatment of various types of cancer ...